These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 8176463

  • 1. Scintigraphic findings of the thyroid in euthyroid ophthalmic Graves' disease.
    Kasagi K, Hidaka A, Misaki T, Miyamoto S, Takeuchi R, Sakahara H, Sasayama S, Iida Y, Konishi J.
    J Nucl Med; 1994 May; 35(5):811-7. PubMed ID: 8176463
    [Abstract] [Full Text] [Related]

  • 2. Thyrotoxic Graves' disease with normal thyroidal technetium-99m pertechnetate uptake.
    Ikekubo K, Hino M, Ito H, Koh T, Ishihara T, Kurahachi H, Kasagi K, Hidaka A, Mori T.
    Ann Nucl Med; 1990 Jul; 4(2):43-8. PubMed ID: 2171608
    [Abstract] [Full Text] [Related]

  • 3. Analysis of the factors associated with Tc-99m pertechnetate uptake in thyrotoxicosis and graves' disease.
    Kidokoro-Kunii Y, Emoto N, Cho K, Oikawa S.
    J Nippon Med Sch; 2006 Feb; 73(1):10-7. PubMed ID: 16538017
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Subclinical Graves' disease as a cause of subnormal TSH levels in euthyroid subjects.
    Kasagi K, Takeuchi R, Misaki T, Kousaka T, Miyamoto S, Iida Y, Konishi J.
    J Endocrinol Invest; 1997 Apr; 20(4):183-8. PubMed ID: 9211123
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. High pre-therapy [99mTc]pertechnetate thyroid uptake, thyroid size and thyrostatic drugs: predictive factors of failure in [131I]iodide therapy in Graves' disease.
    Zantut-Wittmann DE, Ramos CD, Santos AO, Lima MM, Panzan AD, Facuri FV, Etchebehere EC, Lima MC, Tambascia MA, Camargo EE.
    Nucl Med Commun; 2005 Nov; 26(11):957-63. PubMed ID: 16208172
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Low response of the thyroid gland to endogenous thyrotropin increased by thyrotropin-releasing hormone in patients with euthyroid Graves' disease.
    Kashiwai T, Tada H, Watanabe Y, Shimaoka Y, Yagoro A, Hidaka Y, Fujikado T, Amino N.
    Thyroid; 1998 Oct; 8(10):881-5. PubMed ID: 9827654
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [A study using FRTL-5 cell for detecting thyroid stimulating antibody activity in serum in patients with Graves disease].
    Li J, Gao H, Jin SX.
    Zhonghua Nei Ke Za Zhi; 1991 Jul; 30(7):392-4, 454. PubMed ID: 1684315
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.